Throughout 2023, the biopharma sector grappled with dwindling investor confidence, leaving many to wonder just how much lower it could go. As we enter 2024, is there a glimmer of optimism on the horizon? Are there whispers of a turnaround, or do tough challenges still loom ahead?

Our 2024 Preview explores the major narratives shaping biopharma in the coming year – the key companies and therapy areas to watch, the most anticipated drug launches in the pipeline, and the outlook for innovation and regulation. 

We also consider whether the new year will maintain the trend of robust FDA approvals and if funding is beginning to flow more freely. In the midst of a skittish market, we explore what the future holds for both the public and private biopharma sectors. 

HIGHLIGHTS INCLUDE:

Top drugs and companies driving growth

Key products poised for launch
Major players in R&D investment
Likely FDA approval recipients
Money, markets and M&A
New! Galen Growth’s take on digital health in 2024